Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients (ATTeST)
Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effects of Intra-Erythrocyte Dexamethasone Sodium Phosphate on Neurological Symptoms in Patients With Ataxia Telangiectasia
Sponsor: Quince Therapeutics S.p.A.
A PHASE3 clinical study on Genetic Syndrome and Nervous System Disease, this trial is completed. The trial is conducted by Quince Therapeutics S.p.A. and has accumulated 14 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Sep 2021 — Jun 2024 [monthly]
Completed PHASE3
Status: Recruiting → Completed
▶ Show 9 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
Feb 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Sep 2019 — Feb 2020 [monthly]
Recruiting PHASE3
-
Jun 2019 — Sep 2019 [monthly]
Recruiting PHASE3
-
Jan 2019 — Jun 2019 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jan 2019 [monthly]
Recruiting PHASE3
-
Apr 2017 — Jun 2018 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Feb 2017 — Apr 2017 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Quince Therapeutics S.p.A.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Baltimore, United States , Bangalore, India , Brescia, Italy , Chennai, India , Cincinnati, United States , Frankfurt am Main, Germany , Houston, United States , Hyderabad, India , Kochi, India , Leuven, Belgium and 12 more locations